title: Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007.
abstract: OBJECTIVE
  To examine the prevalence of patient-pharmacy staff communication about medications for pain and arthritis and to assess disparities in communication by demographic, socioeconomic, and health indicators.
  
  
  METHODS
  Descriptive, nonexperimental, cross-sectional study.
  
  
  METHODS
  Alabama between 2005 and 2007.
  
  
  METHODS
  687 Patients participating in the Alabama NSAID Patient Safety Study (age >or=50 years and currently taking a prescription nonsteroidal anti-inflammatory drug [NSAID]).
  
  
  METHODS
  Not applicable.
  
  
  METHODS
  Communication with pharmacy staff about prescription and over-the-counter (OTC) NSAIDs was examined before and after adjustment for demographic, socioeconomic, and health indicators.
  
  
  RESULTS
  For the entire cohort (n = 687), mean (+/-SD) age was 68.3 +/- 10.0 years, 72.8% were women, 36.4% were black, and 31.2% discussed use of prescription pain/arthritis medications with pharmacy staff. Discussing use of prescription pain/arthritis medications with pharmacy staff differed by race/gender (P < 0.001): white men (40.3%), white women (34.6%), black men (30.2%), and black women (19.8%). Even after multivariable adjustment, black women had the lowest odds of discussing their medications with pharmacy staff (odds ratio 0.40 [95% CI 0.24-0.56]) compared with white men. For the 63.0% of participants with recently overlapping prescription and OTC NSAID use, communication with pharmacy staff about OTC NSAIDs use was only 13.7% and did not vary significantly by race/gender group.
  
  
  CONCLUSIONS
  Given the complex risks and benefits of chronic NSAID use, pharmacists, pharmacy staff, and patients all are missing an important opportunity to avoid unsafe prescribing and decrease medication adverse events.
authors.affiliation: American Society of Health-System Pharmacists Research and Education Foundation, Bethesda, MD, USA.
authors.forename: Cynthia
authors.initials: C
authors.lastname: LaCivita
authors.forename: Ellen
authors.initials: E
authors.lastname: Funkhouser
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Miller
authors.forename: Midge N
authors.initials: MN
authors.lastname: Ray
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Saag
authors.forename: Catarina I
authors.initials: CI
authors.lastname: Kiefe
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Cobaugh
authors.forename: Jeroan J
authors.initials: JJ
authors.lastname: Allison
mesh_terms: D001741:Black or African American; D000407:Alabama; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D003142:Communication; D003430:Cross-Sectional Studies; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D004366:Nonprescription Drugs / Q000008:administration & dosage; D010146:Pain / Q000188:drug therapy; D010594:Pharmacies; D010595:Pharmacists; D055553:Prescription Drugs / Q000008:administration & dosage; D011369:Professional-Patient Relations; D018570:Risk Assessment; D044465:White People
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004366:Nonprescription Drugs; D055553:Prescription Drugs